retatrutide maximum dose clinical trials Triple hormone receptor agonist for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial Retatrutide Dosing Guide for Researchers

DOSING USED IN PHASE 3 STUDIES In the most recent studies from the TRIUMPH programme (Phase 3) , retatrutide was administered as follows: Route: Subcutaneous Frequency: Once weekly Study duration: Approximately 68 weeks Phase 3 Schedule Recommended Dosage (Clinical Research Escalation Model) Retatrutide is administered once weekly using a gradual dose escalation to improve tolerability

GIP (Glucose-Dependent Insulinotropic Polypeptide) Enhances insulin secretion and metabolic function

Retrieved March 10, 2026, from 9 Chatlani, S

If spontaneous desire has decreased on semaglutide, creating intentional opportunities for physical connection can activate the responsive desire system

Sometimes people call this Ozempic face or GLP-1 face because its so common

Early findings suggest potential effects on alcohol, opioid, and stimulant use, but the research remains limited and inconclusive